Investors may find better financial performance in ImmunoGen Inc. (IMGN)

ImmunoGen Inc. [IMGN] stock is trading at $4.67, up 0.21%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The IMGN shares have gain 3.78% over the last week, with a monthly amount drifted -0.85%, and not seem to be holding up well over a long-time horizon.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


On 4, January 2023, ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). In a post published today on Yahoo Finance, ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on December 29, 2022, and in connection with the previously announced appointment of Michael J. Vasconcelles, MD as ImmunoGen’s Executive Vice President, Research, Development, and Medical Affairs, the compensation committee of the Company’s Board of Directors (the “Compensation Committee”) approved grants of non-qualified stock option awards to purchase 960,000 shares of its common stock (the “Vasconcelles Options”) under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended (the “Inducement Plan”).

From an analyst’s perspective:

ImmunoGen Inc. [NASDAQ: IMGN] stock has seen the most recent analyst activity on November 21, 2022, when Truist initiated its Buy rating and assigned the stock a price target of $10. Previously, Barclays started tracking the stock with Overweight rating on September 09, 2022, and set its price target to $8. On March 21, 2022, downgrade downgraded it’s rating to Sector Perform and revised its price target to $6 on the stock. BMO Capital Markets started tracking the stock assigning a Outperform rating and suggested a price target of $18 on February 11, 2022. Jefferies upgraded its rating to a Buy and raised its price target to $12 on December 01, 2021. In a note dated October 02, 2020, Guggenheim upgraded an Buy rating on this stock but restated the target price of $14.

ImmunoGen Inc. [IMGN] stock has fluctuated between $3.10 and $6.63 over the past year. Currently, Wall Street analysts expect the stock to reach $12.10 within the next 12 months. ImmunoGen Inc. [NASDAQ: IMGN] shares were valued at $4.67 at the most recent close of the market. An investor can expect a potential return of 159.1% based on the average IMGN price forecast.

Analyzing the IMGN fundamentals

ImmunoGen Inc. [NASDAQ:IMGN] reported sales of 15.38 billion for the most recent quarter, which represents a growth of 67.40%. Gross Margin for this corporation currently stands at +97.11% with Operating Margin at -174.80%, Pretax Margin comes in at -199.41%, and Net Margin reading is -199.41%.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.53 points at the first support level, and at 4.40 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.77, and for the 2nd resistance point, it is at 4.87.

ImmunoGen Inc. [IMGN] reported earnings per share of -$0.24 for its fiscal quarter that ended on 6/29/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.21/share, meaning a difference of -$0.03 and a surprise factor of -14.30%. By comparison, the stated earnings for the previous quarter ended on 3/30/2022 were -$0.1 per share as compared to estimates of -$0.21 per share, a difference of $0.11 representing a surprise of 52.40%.

Ratios To Look Out For

For context, ImmunoGen Inc.’s Current Ratio is 3.20. Also, the Quick Ratio is 4.95, while the Cash Ratio stands at 4.74. Considering the valuation of this stock, the price to sales ratio is 21.90, the price to book ratio is 5.02.

Transactions by insiders

We now turn our attention to insider trading, which in the past 3 months has resulted in 1 insider buyings of 25,000 shares and 0 insider sellings of 0 shares.